Mitochondrial Function (eBook)

David Chan, Anne Murphy (Herausgeber)

eBook Download: PDF | EPUB

2014 | 1. Auflage
506 Seiten
Elsevier Science (Verlag)
978-0-12-801615-2 (ISBN)

Infos

This new volume of Methods in Enzymology continues the legacy of this premier serial with quality chapters authored by leaders in the field. Methods to assess mitochondrial function is of great interest to neuroscientists studying chronic forms of neurodegeneration, including Parkinson's, Alzheimer's, ALS, Huntington's and other triplet repeat diseases, but also to those working on acute conditions such as stroke and traumatic brain injury. This volume covers research methods on how to assess the life cycle of mitochondria including trafficking, fusion, fission, and degradation. Multiple perspectives on the complex and difficult problem of measurement of mitochondrial reactive oxygen species production with fluorescent indicators and techniques ranging in scope from measurements on isolated mitochondria to non-invasive imaging of metabolic function. Continues the legacy of this premier serial with quality chapters authored by leaders in the field Covers research methods in biomineralization science Provides invaluable details on state-of-the-art methods to assess a broad array of mitochondrial functions

Inhalt

Front Cover 1
The Use of CRISPR/Cas9, ZFNs, and TALENs in Generating Site-Specific Genome Alterations 4
Copyright 5
Contents 6
Contributors 14
Preface 20
Chapter One: In Vitro Enzymology of Cas9 22
1. Introduction 22
2. Expression and Purification of Cas9 24
Day 1: Cell transformation 25
Day 2: Culture growth and induction 25
Day 3: Cas9 purification by IMAC 26
Day 4: IEX and SEC chromatographic steps 27
Day 5: Concentration and storage 27
3. Preparation of Guide RNAs 28
Day 1: Preparation of transcription template 31
Day 2: In vitro transcription and gel purification 32
Day 3: Gel purification-continued 33
4. Endonuclease Cleavage Assays 34
Substrate preparation 35
Cleavage assay 36
Interpretation of cleavage assays 38
5. Concluding Remarks 38
Acknowledgments 38
References 39
Chapter Two: Targeted Genome Editing in Human Cells Using CRISPR/Cas Nucleases and Truncated Guide RNAs 42
1. Introduction 42
2. Methods 53
2.1. Identification of target sites using ZiFiT 53
Required materials 54
Ensure query sequence is valid 54
Design target sites 55
2.2. Construction of tru-gRNA expression plasmids 57
2.2.1. Reagents 57
2.2.2. Protocol 58
2.3. Transfection of sgRNA and Cas9 expression plasmids into human cells 59
2.3.1. Reagents 60
2.3.2. Protocol 60
2.3.2.1. Prior to Day 1 60
2.4. Quantitative T7EI assays to assess frequencies of targeted genome editing 61
2.4.1. Reagents 61
2.4.2. Protocol 63
Conflict of Interest 65
References 65
Chapter Three: Determining the Specificities of TALENs, Cas9, and Other Genome-Editing Enzymes 68
1. Introduction 69
1.1. Introduction to programmable nucleases for genome editing 69
1.2. Overview of methods to study specificity of genome-editing agents 70
1.2.1. Discrete off-target site testing 70
1.2.2. Genome-wide selections 72
1.2.3. Minimally biased selections in vitro and in cells 74
1.3. Insights and improvements from ZFN specificity studies 78
1.4. Insights and improvements from TALEN specificity studies 80
1.5. Insights and improvements from Cas9 specificity studies 82
2. Methods 86
2.1. Overview of in vitro selection-based nuclease specificity profiling 86
2.2. Pre-selection library design 86
2.3. In vitro selection protocol 87
2.3.1. Before Day 1: Design and synthesize pre-selection library oligonucleotides 87
2.3.2. Day 1: Circularize library oligonucleotides 88
2.3.3. Day 2: Confirm circularization of library oligonucleotides and perform rolling-circle amplification 88
2.3.4. Day 3: Quantify and digest pre-selection library 88
2.3.5. Day 4: PCR of pre- and post-selection libraries 90
2.3.6. Day 5: High-throughput sequencing and analysis 91
2.4. Confirmation of in vitro-identified genomic off-target sites 92
3. Conclusion 94
Acknowledgments 94
References 95
Chapter Four: Genome Engineering with Custom Recombinases 100
1. Introduction 100
2. Target Identification 102
3. Recombinase Construction 103
4. Measurements of Recombinase Activity 106
4.1. Reporter plasmid construction 107
4.2. Luciferase assay 107
5. Site-Specific Integration 108
5.1. Donor plasmid construction 108
5.2. Cell culture methods 109
5.2.1. PCR confirmation of integration 109
5.2.2. Measurements of modification efficiency 110
5.2.3. Isolation and expansion of modified clones 110
6. Conclusions 111
Acknowledgments 111
References 111
Chapter Five: Genome Engineering in Human Cells 114
1. Introduction 115
2. Structure of the Human Genome 116
3. Scope of Human Gene Editing Using Programmable Nucleases 118
3.1. Gene disruption 118
3.2. Gene insertion 119
3.3. Gene correction 119
3.4. Chromosomal rearrangement 119
4. Programmable Nucleases Used for Genome Editing in Human Cells 120
4.1. ZFNs 120
4.2. TALENs 120
4.3. RGENs 123
5. Correction of Human Genetic Diseases Using Programmable Nucleases 124
6. Treatment of Human Nongenetic Diseases Using Programmable Nucleases 126
7. Genome Engineering in Human Pluripotent Stem Cells 127
8. Delivery of Programmable Nucleases to Human Cells 128
9. Nickases for Modifying the Human Genome 130
10. Enrichment of Gene-Edited Human Cells 131
11. Conclusion 132
Acknowledgments 132
References 133
Chapter Six: Genome Editing in Human Stem Cells 140
1. Introduction 141
2. Gene Targeting Strategies 142
3. Choice of Nuclease Targeting Sites 143
4. Experimental Procedures 144
4.1. Human iPSC culture and passaging 145
4.2. Preparation of plasmids for transient transfection 145
4.3. Nucleofection protocol 146
4.4. Verification of successful cutting and gene targeting 148
4.5. Cloning by single cell FACS sorting 149
4.6. Genotyping of clones 150
4.7. Verify iPSC pluripotency and quality 152
5. Alternative Approaches 152
5.1. Low transfection 152
5.2. Viral vectors 153
5.3. Off-targets 154
5.4. Cas9 nickases 155
5.5. Orthogonal Cas9 systems 156
References 156
Chapter Seven: Tagging Endogenous Loci for Live-Cell Fluorescence Imaging and Molecule Counting Using ZFNs, TALENs, and Cas9 160
1. Introduction 161
2. Methods 163
2.1. Donor plasmid design 163
2.1.1. Required materials 165
2.1.2. Option 1: Gibson assembly 165
2.1.3. Option 2: Classical cloning method 166
2.2. Generation of genome-edited cell lines using CRISPR, TALENs, or ZFNs 167
2.2.1. Required materials 167
2.2.2. Preparation of cells 168
2.2.3. Electroporation 170
2.2.4. Isolation of genome-edited cells 171
Genomic DNA extraction 173
PCR and sequencing 173
By immune blot: 174
By immunofluorescence microscopy 175
3. Tagging/Editing Limitations 175
4. Perspectives 177
4.1. Efficiency of cellular processes: Example of clathrin-mediated endocytosis 177
4.2. Quantification of protein stoichiometry in specific structures within genome-edited cells 177
4.3. Genome-edited stem cells: A new model for mammalian cell biology studies 178
Acknowledgments 179
References 179
Chapter Eight: Genome Editing Using Cas9 Nickases 182
1. Introduction 183
2. Target Selection 185
3. Plasmid sgRNA Construction 186
4. Validation of sgRNAs in Cell Lines 187
5. Cell Harvest and DNA Extraction 188
6. SURVEYOR Indel Analysis 189
7. HDR and Non-HDR Insertion Using Cas9n 191
8. Analysis of HDR and Insertion Events 192
9. Troubleshooting 193
Acknowledgments 194
References 194
Chapter Nine: Assaying Break and Nick-Induced Homologous Recombination in Mammalian Cells Using the DR-GFP Reporter and C... 196
1. Introduction 197
2. Cloning the Nickase and Catalytically Dead Variants of Cas9 198
2.1. The Cas9 endonuclease 198
2.2. Generating Cas9H840A and Cas9D10A/H840A expression vectors 200
2.3. Cloning and verifying the constructs 201
3. Selection of the Target Site and Cloning of sgRNA Constructs 202
3.1. Selecting suitable target sequences 202
3.2. Cloning the guide RNA constructs 203
4. Cell Transfection and FACS Analysis 204
4.1. Transfection 206
4.2. Analysis and interpretation of the results 209
5. Materials 210
5.1. Cloning 210
5.2. Cell culture, transfections, data collection, and analysis 210
6. Summary 211
References 211
Chapter Ten: Adapting CRISPR/Cas9 for Functional Genomics Screens 214
1. Introduction 215
2. Altering the Vector Design for High-Throughput Screens 216
3. Construction of sgRNA Libraries 220
3.1. Guide sequence prediction 220
3.2. Cloning of guide templates 223
3.2.1. Layout of the guide template 223
3.2.2. Initial guide library preparation 224
3.2.3. PCR amplification of pooled oligonucleotide templates 224
Reagent amounts 224
Thermocycler reaction conditions 224
Reagent amounts 224
Thermocycler reaction conditions 225
3.2.4. Digestion and ligation of the guides into vector backbone 225
3.2.5. Assessing ligation efficiency 225
3.2.6. Large-scale transformation of the guide library 225
3.2.7. Checking the quality of the guide library 226
3.2.8. Bulk harvesting of bacterial-transformed guide library 226
3.2.9. Arraying individual bacterial guide library clones 226
4. Retroviral Transduction of the Guide Library 227
5. Notes on Screening Design Parameters 228
6. Decoding ``Hits´´ from Positive Selection Screens Involving sgRNA Library Pools 231
Reagent amounts 231
Thermocycler reaction conditions 231
7. Conclusion 232
References 232
Chapter Eleven: The iCRISPR Platform for Rapid Genome Editing in Human Pluripotent Stem Cells 236
1. Introduction 237
2. Generation of iCas9 hPSCs 241
2.1. Vector design 243
2.1.1. TALEN vectors 243
2.1.2. Donor vectors 243
2.2. hPSC electroporation 243
2.3. Selection and expansion of clonal lines 245
2.4. Genotyping by Southern blot 246
2.5. Validation 250
2.5.1. RT-PCR analysis 250
2.5.2. Immunohistochemical analysis of pluripotency marker expression 251
2.5.3. Teratoma assay 251
3. Generation of Knockout hPSCs Using iCRISPR 252
3.1. sgRNA design 252
3.2. sgRNA production 252
3.2.1. PCR amplification of in vitro transcription (IVT) DNA templates 252
3.2.2. In vitro transcription and purification of sgRNAs 254
3.3. Single or multiplex sgRNA transfection in hPSCs 254
3.4. Assessment of Indel frequency 255
3.4.1. PCR amplification of the CRISPR target region 255
3.4.2. Quantification of Indels through T7EI assay 256
3.4.2.1. Hybridization 256
3.4.2.2. Digestion 256
3.4.2.3. Quantification 257
3.4.3. Quantification of Indels through RFLP assay 257
3.4.3.1. Digestion 257
3.4.3.2. Quantification 257
3.5. Clonal expansion of knockout lines 258
3.5.1. Replating and colony picking 258
3.5.2. Colony screening 258
3.5.2.1. Lysis 259
3.5.2.2. PCR and sequencing 259
3.5.3. Validation 260
3.5.3.1. Validation of the mutant alleles 260
3.5.3.2. Off-target analysis 260
4. Generation of Precise Nucleotide Alterations Using iCRISPR 260
4.1. Design of ssDNA as HDR templates 261
4.2. ssDNA/sgRNA cotransfection in hPSCs 262
4.3. Establishment of clonal lines 262
5. Inducible Gene Knockout in hPSCs Using iCRISPR 263
5.1. Inducible gene knockout through sgRNA transfection 264
5.2. Inducible gene knockout through using iCr hPSC lines 264
6. Conclusions and Future Directions 265
6.1. Anticipated results 265
6.2. In-frame mutations 265
6.3. Cross contamination 266
6.4. Time and throughput considerations 266
6.5. Off-target considerations 266
6.6. Additional use and extension of the iCRISPR platform 267
Acknowledgments 268
References 268
Chapter Twelve: Creating Cancer Translocations in Human Cells Using Cas9 DSBs and nCas9 Paired Nicks 272
1. Introduction 273
2. Materials 275
2.1. Cas9, nCas9, and sgRNA expression plasmid preparation 275
2.2. Cell culture and transfection 275
2.3. T7 endonuclease I assay 276
2.4. PCR detection of translocations 276
2.5. PCR quantification of translocations 276
3. Methods to Induce and Detect Cancer Translocations in Human Cells 277
3.1. sgRNA design and expression plasmid construction 277
3.2. Cell transfections with sgRNA and Cas9 or nCas9 expression plasmids 281
3.3. T7 endonuclease I assay to estimate cleavage efficiency 283
3.4. PCR-based translocation detection 284
3.5. Quantification of potential off-target cleavage 285
3.6. Quantification of translocation frequency using a 96-well plate screen 287
3.7. Translocation frequency determination by serial dilution 289
4. Conclusions 290
Acknowledgments 290
References 290
Chapter Thirteen: Genome Editing for Human Gene Therapy 294
1. Introduction 295
2. Genome Editing of B2M in Primary Human CD4+ T Cells 297
2.1. Required materials 298
2.2. Isolation of CD4+ T cells from peripheral blood 299
Notes 300
2.3. Delivery of CRISPR/Cas9 by nucleofection 300
2.3.1. Nucleofection 301
2.3.2. Postnucleofection 303
Notes 303
2.4. Evaluation of targeting efficiency 303
2.4.1. FACS-based analysis 304
2.4.2. PCR-based screening assay 305
Notes 306
3. Targeting of CCR5 in Human CD34+ HSPCs Using CRISPR/Cas9 307
3.1. Required materials 309
3.2. Transfection of CD34+ HSPCs 310
3.2.1. Isolation of CD34+ HSPCs from cord blood 310
3.2.2. Nucleofection of CD34+ HSPCs 311
3.2.3. Cell sorting 311
Notes 312
3.3. Colony-forming cell assay 312
Notes 313
3.4. Clonal analysis 313
Notes 314
References 314
Chapter Fourteen: Generation of Site-Specific Mutations in the Rat Genome Via CRISPR/Cas9 318
1. Theory 319
2. Equipment 321
3. Materials 322
3.1. Solutions and buffers 323
4. Protocol 324
4.1. Preparation 324
4.2. Duration 324
4.3. Caution 325
5. Step 1: In Vitro Transcription of sgRNA Target Oligonucleotides 325
5.1. Overview 325
5.2. Duration 325
5.3. Tip 326
6. Step 2: In Vitro Transcription of Cas9 mRNA 328
6.1. Overview 328
6.2. Duration 328
6.3. Tip 329
7. Step 3: Preparation of Pseudopregnant Female Rats and One-Cell Rat Embryos 330
7.1. Overview 330
7.2. Duration 330
7.3. Tip 330
7.4. Tip 331
7.5. Tip 331
8. Step 4: Microinjection of One-Cell Embryos and Transplanting the Embryos into Pseudopregnant Rats 332
8.1. Overview 332
8.2. Duration 332
8.3. Tip 333
8.4. Tip 333
8.5. Tip 333
8.6. Tip 333
8.7. Tip 333
8.8. Tip 335
9. Step 5: Identification of Founder Rats 335
9.1. Overview 335
9.2. Duration 335
9.3. Tip 336
9.4. Tip 336
10. Step 6: Production of F1 Generation Rats 338
10.1. Overview 338
10.2. Duration 338
10.3. Tips 338
References 338
Chapter Fifteen: CRISPR/Cas9-Based Genome Editing in Mice by Single Plasmid Injection 340
1. Introduction 341
2. Design and Construction of CRISPR/Cas9 Plasmids with pX330 343
2.1. Selection and off-target analysis of sgRNA in targeted gene 343
2.1.1. Design of sgRNAs against the target gene: Protocol 344
2.2. Construction of pX330 with designed sgRNA 344
2.2.1. Insertion of sgRNA into the pX330 plasmid: Protocol 344
3. Validation of pX330 In Vitro 347
3.1. Construction of pCAG-EGxxFP with the targeted genomic region 347
3.1.1. Insertion of the target genomic fragment into pCAG-EGxxFP plasmid: Protocol 348
3.2. Cotransfection of pX330-sgRNA and pCAG-EGxxFP-target into HEK293T cells 349
3.2.1. Cell culture and transfection in HEK293T cells: Protocol 349
3.3. Observation of EGFP fluorescence in the transfected cells 350
4. One-Step Generation of Mutant Mice Via Circular Plasmid Injection 351
4.1. Collecting the fertilized eggs 351
4.1.1. Superovulation treatment and collection of fertilized eggs: Protocol 351
4.2. Preparing pX330-sgRNA plasmid for microinjection 351
4.2.1. Preparation of pX330-sgRNA plasmid for microinjection: Protocol 352
4.3. Pronuclear microinjection of circular pX330-sgRNA plasmid 352
4.3.1. Manipulating mouse embryos and microinjection system: Protocol 352
5. Screening for Targeted Mutation in Mice 353
5.1. Direct sequencing of PCR products: Protocol 353
6. Concluding Remarks 353
Acknowledgment 356
References 356
Chapter Sixteen: Imaging Genomic Elements in Living Cells Using CRISPR/Cas9 358
1. Introduction 359
1.1. Choice of target sites and DNA recognition methods 359
1.2. Sensitivity and specificity of genome imaging using CRISPR/Cas9 361
2. Generation of Cell Lines Stably Expressing dCas9-GFP 362
2.1. Generation of dCas9-GFP constructs 362
2.2. dCas9-GFP/Tet-On 3G lentiviral production 363
2.3. dCas9-GFP/Tet-On 3G lentiviral infection 364
2.4. Selection of clonal cell lines stably expressing dCas9-GFP 366
3. Expression of sgRNAs Using Lentiviral Vector 367
3.1. sgRNA design and cloning 367
3.2. sgRNA lentiviral infection 368
4. Labeling of Nonrepetitive Sequences 368
4.1. Target selection and sgRNA design 368
4.2. High-throughput sgRNA cloning 369
4.3. Production of pooled sgRNA lentiviruses 370
5. Imaging of Genomic Loci Detected by CRISPR 370
5.1. Verify CRISPR signal by a modified FISH staining protocol 370
5.2. Live-cell imaging of genomic loci 371
6. Summary 373
Acknowledgments 374
References 374
Chapter Seventeen: Cas9-Based Genome Editing in Xenopus tropicalis 376
1. Introduction 377
2. Principle 378
3. Protocol 380
3.1. Background knowledge and experimental equipment 380
3.2. sgRNA design 380
3.2.1. Considerations in target site choice 382
3.3. sgRNA template construction 383
3.3.1. Template assembly by PCR: Primers 383
3.3.2. Template assembly by PCR: Assembly conditions 383
3.3.3. In vitro transcription of sgRNA 384
3.4. Procedure for microinjection 385
3.4.1. Doses of sgRNA and Cas9 385
3.4.2. Sidebar: Cas9 protein in vitro cleavage assays 388
3.4.3. Procedure for embryo microinjection 388
3.5. Assessment of mutagenesis: Genotyping 389
3.5.1. Embryo lysis and PCR 389
3.5.2. Evaluation of sequencing results and subsequent identification of specific indels 390
4. Discussion 391
4.1. Multiple targeting strategy: Avoiding off-target problems and simpler genotyping of F1 animals 391
4.2. Further applications of CRISPR-mediated mutagenesis in Xenopus 393
Acknowledgments 394
References 394
Chapter Eighteen: Cas9-Based Genome Editing in Zebrafish 398
1. Introduction 399
1.1. CRISPR/Cas adaptive immunity 399
1.2. The Type II CRISPR/Cas system 400
1.3. The development of CRISPR/Cas genome-editing technology 401
1.4. The zebrafish animal model and CRISPR/Cas 404
2. Targeted Generation of Indel Mutations 406
2.1. Cas9 modification and delivery platforms 406
Protocol for preparation of SpCas9 mRNA for microinjection 407
2.2. Single-guide RNA design considerations 409
Protocol for preparation of sgRNAs for microinjection: 413
2.3. Introduction and identification of Cas9-sgRNA-induced indels 416
3. Other Targeted Genome-Editing Strategies 417
3.1. Precise sequence modifications mediated by single-stranded oligonucleotides 417
3.2. Targeted integration of long DNA fragments 418
3.3. Chromosomal deletions and other rearrangements 421
4. Future Directions 422
Acknowledgments 424
References 424
Chapter Nineteen: Cas9-Based Genome Editing in Drosophila 436
1. Introduction 436
2. Applications and Design Considerations for CRISPR-Based Genome Editing 438
2.1. Selection of sgRNA target sites 440
2.2. Tools facilitating sgRNA design 441
3. Delivery of CRISPR Components 442
4. Generation of CRISPR Reagents 444
4.1. Cloning of sgRNAs into expression vectors 445
Materials 446
Protocol 446
4.2. Cloning of donor constructs 447
Materials 448
Protocol 449
4.3. Isolation of in vivo genome modifications 450
5. Detection of Mutations 450
5.1. Preparation of genomic DNA from fly wings 451
5.1.1. Restriction profiling 452
Materials 452
Protocol 452
5.1.2. Surveyor assay to detect indels 453
Materials 454
Protocol 454
5.1.3. Detection of mutations using HRMA 455
Materials 456
Protocol 456
5.2. Analysis of HRMA data 457
Acknowledgments 457
References 458
Chapter Twenty: Transgene-Free Genome Editing by Germline Injection of CRISPR/Cas RNA 462
1. Theory, Philosophy, and Practical Considerations 463
1.1. Overview 463
1.2. When to use or not to use transgenes for delivery of CRISPR/Cas 464
1.3. Altered mutation profile from transgene-free treatment with CRISPR/Cas 465
1.4. A note on specificity of CRISPR/Cas cleavage 467
2. Equipment 467
3. Materials 468
4. Identifying a Target Sequence 468
5. Generating Your sgRNA Construct 470
5.1. Oligonucleotide design 470
5.2. Insert generation 470
5.3. Preparation of linearized vector for the sgRNA construct 471
5.4. Construction and identification of sgRNA synthesis plasmid 471
6. In Vitro Synthesis of sgRNA 472
6.1. Linearization of sgRNA template plasmid 472
6.2. In vitro transcription to generate sgRNA 473
6.3. Purification of in vitro-transcribed sgRNA 473
7. In Vitro Synthesis of hCas9 mRNA 473
7.1. Linearization of SP6-hCas9-Ce-mRNA plasmid 473
7.2. In vitro transcription of hCas9 mRNA 474
7.3. Polyadenylation of in vitro-transcribed hCas9 mRNA 474
7.4. Purification of in vitro-transcribed, polyadenylated hCas9 mRNA 474
8. Injection of sgRNA and mRNA 474
9. Recovery of Mutants Generated Using CRISPR/Cas 475
9.1. Recovery and plating of injected animals 475
9.2. Identification of animals carrying mutations induced by CRISPR/Cas 476
References 476
Chapter Twenty-One: Cas9-Based Genome Editing in Arabidopsis and Tobacco 480
1. Introduction 481
2. Cas9 and sgRNA expression 482
3. Dual sgRNA-Guided Genome Editing 484
3.1. Designing and constructing dual sgRNAs 484
3.2. Transfecting and expressing Cas9/sgRNAs in protoplasts 485
3.3. Evaluating the frequency of targeted genome modifications 486
4. Perspectives 488
5. Notes 489
Acknowledgments 491
References 491
Chapter Twenty-Two: Multiplex Engineering of Industrial Yeast Genomes Using CRISPRm 494
1. Introduction 495
2. Plasmid Design 497
3. Cas9 Expression 499
4. Guide RNA Expression 499
5. Screening Method 502
5.1. Cloning the target sequence into pCAS 503
5.2. Double-stranded linear DNA repair oligos 503
5.3. CRISPRm screening consists of the cotransformation of pCAS and the double-stranded linear DNA homologous repair template 504
5.4. Industrial yeast 506
5.5. Markerless gene assembly in the yeast chromosome 506
6. Concluding Remarks 508
Acknowledgments 509
References 509
Chapter Twenty-Three: Protein Engineering of Cas9 for Enhanced Function 512
1. Introduction 513
1.1. The structure of Cas9 515
1.2. Current uses 518
1.3. Initial engineering questions 518
2. Methods 519
2.1. A note on applications 519
2.2. Electrocompetent E. coli preparation for library construction 520
2.3. Discovery of functional, engineered, variants of Cas9 proteins 521
2.4. Screening Cas9 521
2.5. Selecting Cas9 521
2.6. Screening for functional Cas9 variants 523
2.7. Determining screening enrichment of PDZ-dCas9 domain insertions 525
2.8. Identifying and testing PDZ-Cas9 clones from a screened library 527
2.9. Expanding horizons 528
3. Conclusion 529
References 529
Author Index 534
Subject Index 560
Color Plate 572

Textauszug

Contributors

Hossein Aleyasin,     Department of Neurology and Neuroscience, The Burke Medical Research Institute, Weill Medical College of Cornell University, White Plains, and Fishberg Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, USA

Ishraq Alim,     Department of Neurology and Neuroscience, The Burke Medical Research Institute, Weill Medical College of Cornell University, White Plains, New York, USA

A. Ambrus,     Department of Medical Biochemistry, Semmelweis University, and MTA-SE Laboratory for Neurobiochemistry, Budapest, Hungary

Estela Area-Gomez,     Department of Neurology, Columbia University Medical Center, New York, USA

Sandra R. Bacman,     Department of Neurology, University of Miami School of Medicine, Miami, Florida, USA

Stephen D. Baird,     Children’s Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada

Irene Bolea,     Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, USA

David C. Chan,     Division of Biology and Biological Engineering, and Howard Hughes Medical Institute, California Institute of Technology, Pasadena, California, USA

Guo Chen,     State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Protein Science, College of Life Sciences, Nankai University, Tianjin, China

Linbo Chen,     State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Protein Science, College of Life Sciences, Nankai University, Tianjin, China

Quan Chen,     State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Protein Science, College of Life Sciences, Nankai University, Tianjin, and State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China

Andy Cheuk-Him Ng,     Children’s Hospital of Eastern Ontario Research Institute, and Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Ontario, Canada

Megan M. Cleland,     Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Swathi Devireddy,     Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA

Ajit S. Divakaruni,     Department of Pharmacology, University of California, San Diego, California, USA

Du Feng,     Guangdong Key laboratory of Age-related Cardiac-cerebral Vascular Disease, Institute of Neurology, Guangdong Medical College, Zhanjiang, Guangdong Province, China

David A. Ferrick,     Seahorse Bioscience, Billerica, Massachusetts, USA

Wen-Biao Gan,     Department of Physiology and Neuroscience, Skirball Institute, New York University School of Medicine, New York, USA

Elisabeth Garland-Kuntz,     Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA

Shealinna X. Ge,     Department of Anesthesiology and Center for Shock, Trauma and Anesthesiology Research (STAR), University of Maryland School of Medicine, Baltimore, Maryland, USA

Roberta A. Gottlieb,     Department of Molecular Cardiobiology, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA

Hengchang Guo,     Department of Neurology and Neuroscience, The Burke Medical Research Institute, Weill Medical College of Cornell University, White Plains, New York, and Fischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA

Renee E. Haskew-Layton,     Department of Neurology and Neuroscience, The Burke Medical Research Institute, Weill Medical College of Cornell University, White Plains, and Department of Health and Natural Sciences, Mercy College, Dobbs Ferry, New York, USA

Riikka H. Hämäläinen,     Research Programs Unit, Molecular Neurology, Biomedicum-Helsinki, University of Helsinki, Helsinki, Finland

Peter J. Hollenbeck,     Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA

Gregory P. Holmes-Hampton,     Molecular Medicine Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA

Martin Jastroch,     Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

Mariusz Karbowski,     Center for Biomedical Engineering and Technology, and Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA

Adam L. Knight,     Synaptic Function Section, The Porter Neuroscience Research Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA

Pin-Chao Liao,     Department of Biological Sciences, Purdue University, West Lafayette, Indiana, USA

Mei-Yao Lin,     Synaptic Function Section, The Porter Neuroscience Research Center, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA

Lei Liu,     State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China

Jordi Magrané,     Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, USA

Giovanni Manfedi,     Brain and Mind Research Institute, Weill Medical College of Cornell University, New York, USA

Thomas Misgeld,     German Center for Neurodegenerative Diseases (DZNE); Munich Center for Systems Neurology (SyNergy), and Institute of Neuronal Cell Biology, Technische Universität München, Munich, Germany

Carlos T. Moraes,     Department of Neurology, University of Miami School of Medicine, Miami, Florida, USA

Anne N. Murphy,     Department of Pharmacology, University of California, San Diego, California, USA

David G. Nicholls,     Department of Clinical Sciences in Malmö, Unit of Molecular Metabolism, Lund University Diabetes Centre, CRC, Malmö, Sweden, and Buck Institute for Research on Aging, Novato, California, USA

Dominik Paquet,     Adolf-Butenandt-Institute, Biochemistry, Ludwig-Maximilians-University, and German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

Alexander Paradyse,     Department of Pharmacology, University of California, San Diego, California, USA

Guy A. Perkins,     National Center for Microscopy and Imaging Research, University of California, San Diego, California, USA

Anh H. Pham,     Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA

Milena Pinto,     Department of Neurology, University of Miami School of Medicine, Miami, Florida, USA

Gabriela Plucińska,     Munich Center for Systems Neurology (SyNergy), Munich, Germany

Brian M. Polster,     Department of Anesthesiology and Center for Shock, Trauma and Anesthesiology Research (STAR), and Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA

Rajiv R. Ratan,     Department of Neurology and Neuroscience, The Burke Medical Research Institute, Weill Medical College of Cornell University, White Plains, New York, USA

Brian A. Roelofs,     Center for Biomedical Engineering and Technology, and Department of Biochemistry and Molecular Biology,...

Produkt-Details

• Erscheint lt. Verlag: 10.11.2014
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie
• Themenwelt: Naturwissenschaften ► Biologie ► Biochemie
• Themenwelt: Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie
• Themenwelt: Naturwissenschaften ► Biologie ► Zellbiologie
• Themenwelt: Naturwissenschaften ► Physik / Astronomie ► Angewandte Physik
• ISBN-10: 0-12-801615-9 / 0128016159
• ISBN-13: 978-0-12-801615-2 / 9780128016152